A New Patient Powerhouse
presented by
ERIKA HANSON BROWN
A Project of

Erika Hanson Brown

Founder and creator of Colontown

One Cancer Place - where patients align with innovation. 

We would be in NOWHERESVILLE without the wonderful friends, supporters, stakeholders, patients, business leaders, and organizational collaborators who have donated so much of their time, belief in, intellectual and social capital in our ground-breaking effort to change the entire landscape of cancer care. 

ONE CANCER PLACE is the classic case of the "it takes a village" concept. We are so proud that you choose to help us with this enormous task: helping to save the lives of more cancer patients. We call you "The People", but that name doesn't begin to convey the enormity of your donation of YOU to our nascent effort.  

THANK YOU, OUR PEOPLE!


Erika Hanson Brown

CEO/Founder

ONE CANCER PLACE Inc.

Denver, CO

Erika Hanson Brown is CEO and founder of ONE CANCER PLACE, the non-profit organization that is the newest iteration of the development of the formidable PATIENT POWERHOUSE(™) concept, a Brown design. The new POWERHOUSE leads the cancer patient communities in providing the foundation for patient education and trailblazing leadership in the oncoming “molecular revolution” in cancer care.

Erika believes that she is fortunate to have learned that there are three aspects of life that make her life worth living: GOOD HEALTH, HEALTHY PURPOSE, and LOVE. Her life today is abundant with all three, and she wishes to share this learning with all of her cancer stakeholder friends for the rest of her life.


Andrea Downing

Co-Founder

The Light Collective

Portland, OR

Andrea Downing is a BRCA Community Data Organizer and an ePatient security researcher. In 2018, Andrea discovered a security vulnerability which affected the privacy and safety of all closed groups on Facebook and launched a congressional inquiry.

Her work has been featured on CNN, Fortune, and The Verge, and has catalyzed an urgent dialogue on national health privacy policy and the need for protections outside of HIPAA. Andrea has co-founded a nonprofit called The Light Collective to work with vulnerable patient groups seeking digital rights and safe spaces for patient support communities on social media.


Teri Griege

President & Founder

Powered by Hope Foundation

St. Louis, MO

Teri Griege is a competitive triathlete, marathoner and Ironman who shares her moving story as she continues her fight with Stage IV colon cancer.

In 2009, Teri was diagnosed with Stage IV cancer and given a six percent chance of survival. Despite the devastating prognosis, Teri refused to let the disease get in the way of her dream, competing in The Ironman World Championship in Hawaii. In 2011, while still undergoing chemo, she crossed the finish line. Teri has raced in all six World Marathon Majors and the 70.3 World Championship, and she continues to train and compete in races around the country.

As part of her mission to save lives and inspire hope, she recently published her book, Powered By Hope, the Teri Griege Story, with author Amy Marxkors. In the book, she goes deeper into her story of love, loss and finding hope in the face of adversity. As she writes, “Everyone has a cancer. Everyone has a dream.”

Teri has been a guest speaker for major organizations and has appeared on both on The Today Show, ESPN, NBC, and the Ellen DeGeneres Show’s Good News Blog. Upon hearing Teri speak, Sports Emmy Award winner Joe Buck said that Teri’s story “would inspire even the most hardened cynic.” Teri has received awards locally and nationally for her work in health awareness and fundraising, including the Colon Cancer Alliance Sapphire Award, the Women of Achievement Award in St. Louis and the WunderGlo Foundation Cancer Warrior award. She started the Powered By Hope Foundation to provide hope and support to anyone undergoing cancer treatment through the presentation of a medal with words of inspiration. The medal is given to patients to remind them that they are not alone and share hope as they face the challenges ahead.


Christopher Heery, M.D.

Chief Medical Officer

Arcellx, Inc.

Gaithersburg, MD

Dr. Heery has served as Chief Medical Officer of Precision BioSciences and Bavarian Nordic. At Precision, he oversaw the clinical development of one of the first allogeneic CAR T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. While at Bavarian Nordic, he oversaw clinical development programs for its immune-oncology and infectious disease vaccine portfolio.

Prior to his roles in biotech, he was head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI). He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also held an Adjunct Appointment in the Genitourinary Malignancies Branch. At NCI, Dr. Heery was part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer.

Dr. Heery is board certified in Medical Oncology and Internal Medicine and completed his internal medicine residency at the University of Illinois at Chicago after receiving his M.D. from East Carolina University Brody School of Medicine. Dr. Heery also holds a B.A. in English Literature from Duke University.


Eric Hoffman

Public Affairs Strategist

Schmidt Public Affairs

Alexandria, VA

Eric Hoffman is a Senior Counselor at Schmidt Public Affairs. He brings nearly thirty years’ experience in public affairs, corporate communications and advocacy. Eric’s healthcare portfolio focuses on health technology, medical devices, value assessment and healthcare delivery.

PEric builds and executes strategic communications programs that achieve reputational, legislative and regulatory objectives. He is skilled at creating and managing integrated campaigns the leverage earned media, content strategy, third-party validation, grassroots activations and analytics to achieve results.

In his professional career, Eric has been a press secretary on Capitol Hill, worked to raise infant immunization rates at the U.S. Department of Health and Human Services, served as spokesman for then-first-time Senate candidate Mark Warner and worked for numerous fascinating clients during the last twenty years at two multi-national PR agencies.

Eric lives in Bethesda, MD with his wife, two teenagers and incredibly cute dog. When he’s not working, Eric is most likely playing basketball, swimming or dealing with those teenagers.


Christopher Lieu, M.D.

Associate Director
Clinical Research

Director Medical Oncology

University of Colorado
Cancer Center

Aurora, Colorado

Dr. Lieu joined the University of Colorado School of Medicine faculty in July 2011. He trained in internal medicine at the University of Colorado, where he served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and also served as the Chief Medical Oncology Fellow. Dr. Lieu is the Associate Director for Clinical Research and Director of GI Medical Oncology at the University of Colorado Cancer Center, the Vice-Chair of the National Cancer Institute Colon Cancer Task Force, serves on the FDA Oncologic Drugs Advisory Committee, and he serves on the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers.

Fellowship Training
University of Texas MD Anderson Cancer Center

ResidencyTraining
University of Colorado

Medical Schools
MD, Wake Forest University School of Medicine


Pam Ostby, Ph.D

Oncology Nurse Educator

Research Specialist

St. Louis, MO

Oncology Certified Nurse with PhD education experienced in patient-centric care, research, clinical trials, education, and relationship building. Special interests include disease state education program development and potential benefits of targeted diagnostics, treatment, and immunological advances. Patient advocate at all levels, especially in driving increased stakeholder education relevant to available treatment options based on molecular profiling.


Thomas M. Parry

Marzouk & Parry pllc

Washington, DC

Mr. Parry is a partner with the Marzouk & Parry law firm. He has served as Chair of the Computer Law Section of the District of Columbia Bar and as an officer of the D.C. Computer Law Forum. He has spoken frequently on legal issues facing high technology industries and is the author of two books on IP rights and technology licensing, distribution and protection. Mr. Parry received his undergraduate degree from Colorado College and a masters degree from Rutgers University. His law degree is from Georgetown University, where he served on the editorial board of the Georgetown Law Journal.

Marzouk & Parry focuses on representing high technology companies: Internet and e-commerce companies and web-based application service providers, software developers and distributors, IT outsourcing service providers, and IT government contractors. The firm counsels businesses on a wide range of intellectual property rights, including copyright, trade secret, trademark and domain name matters, as well as technology development and acquisition, licensing, marketing, joint venture and other contracts. The firm also advises businesses on formation and corporate matters, including shareholders and LLC agreements and stock and asset purchase transactions, and provides counsel regarding employment law matters, including employment, nondisclosure and noncompete agreements.

The firm has as active practice in the health care sector, representing IT software and infrastructure providers, associations and research entities in the health care and research fields.


Michael Sapienza

CEO Colorectal Cancer Alliance

Washington, DC

Michael Sapienza is the Chief Executive Officer of the Colorectal Cancer Alliance, the largest colon cancer advocacy group in the country. He lost his mother to colorectal cancer in May 2009. He turned his profound grief into action, inspiring and challenging the colorectal cancer community, family, friends, and professional associates to follow his lead and dedicate themselves to ending colorectal cancer within our lifetime—the mission of the Colorectal Cancer Alliance. Michael founded The Chris4Life Colon Cancer Foundation and served as its President from 2010-2015. In 2016, he led the team that merged the Foundation and the Colon Cancer Alliance, creating the nation’s largest colon cancer specific nonprofit, which changed its name to Colorectal Cancer Alliance in 2017 to embrace both the colon and rectal cancer communities.

Over the last decade, Michael has become an expert and trusted voice on the topics of colorectal cancer prevention, patient care, and medical research. Michael regularly appears on TV and radio programs throughout the United States, including NBC’s TODAY show. He is frequently quoted in national publications such as USA Today, Newsweek, and The New York Times, promoting awareness and the importance of increased funding for colorectal cancer research and early detection.

Michael is a member of The Ruesch Center for the Cure of GI Cancer’s Advisory Board at Georgetown University, and in 2020 he was appointed to the President’s Cancer Panel and NCCRT’s 2021 Steering Committee. In 2014, Michael received three prestigious industry awards: David Jagelman, MD Award for advocacy in Colorectal Cancer Awareness by the American Society of Colon and Rectal Surgeons; the Public Service Award from the Society for Surgery of the Alimentary Tract; and the Champion Award from Preventing Colorectal Cancer. In 2018, Michael was honored with a Luminary Award from OncLive and The Ruesch Center for his lifetime commitment to improving the lives of patients affected by gastrointestinal cancer.

Michael holds degrees from both Northwestern University and Rice University and currently resides in the District of Columbia.


Eli Van Allen, M.D.

Associate Professor Harvard Medical School

Associate Member: Broad Institute

Dana-Farber/Partners Cancer Care

Boston, MA

Dr. Van Allen is an Associate Professor of Medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an Associate Member at the Broad Institute of MIT and Harvard. His research focuses on computational cancer genomics, the application of new molecular profiling technologies to advance precision cancer medicine, and studying resistance to cancer therapeutics. As both a computational biologist and medical oncologist, he has specific expertise in clinical computational oncology and the development of algorithms to analyze and interpret genomic data for clinically focused questions. Overall, his research contributes to the field of precision cancer medicine and resistance to targeted therapeutics via expertise and study in translational and clinical bioinformatics.

Originally from Los Angeles, CA, he studied Symbolic Systems at Stanford University, obtained his M.D. from UCLA, and completed a residency in internal medicine at UCSF before coming to Boston and completing a medical oncology fellowship at the Dana-Farber/Partners Cancer Care program.